EGFR和KRAS在上皮性卵巢癌组织中的表达及临床意义

目的:探讨表皮生长因子受体(EGFR)和鼠Kirsten肉瘤病毒致癌基因(KRAS)蛋白在上皮性卵巢癌组织中的表达水平及临床意义。方法:利用免疫组化SP法对上皮性卵巢癌组织(病例组,n=57)、卵巢良性肿瘤组织(良性组,n=50)以及正常卵巢组织(对照组,n=50)中的EGFR、KRAS蛋白水平进行检测,并分析其在上皮性卵巢癌发生发展中的作用。结果:病例组的EGFR、KRAS蛋白阳性率高于良性组和对照组(P0.05),良性组和对照组的EGFR、KRAS蛋白阳性率差异无统计学意义(P0.05)。浆液性腺癌组EGFR、KRAS蛋白的阳性表达率高于非浆液性腺癌组,Ⅲ~Ⅳ期的上皮性卵巢癌组织中EGFR、KRAS蛋白阳性表达率高于Ⅰ~Ⅱ期,中、低分化组中EGFR、KRAS蛋白阳性表达率高于高分化组,差异均具有统计学意义(P0.05)。上皮性卵巢癌组织中EGFR与KRAS的蛋白的阳性表达率呈正相关关系(r=0.469,P0.05)。结论:EGFR及KRAS蛋白在上皮性卵巢癌组织中的表达水平明显升高,可能参与了上皮性卵巢癌的发生发展过程,且两者之间呈正相关关系,联合检测可作为早期诊断上皮性卵巢癌的重要指标。

Expression of EGFR and KRAS in Patients with Epithelial Ovarian Cancer and Its Clinical Significance

ABSTRACT Objective: To explore the expression level and clinical significance of epidermal growth factor receptor(EGFR)and Kirsten rat sarcoma viral proto-oncogene(KRAS)protein in patients with epithelial ovarian cancer. Methods: The EGFR and KRAS pro- tein levels of epithelial ovarian cancer tissue(cases group, n=57), benign ovarian tumor tissue(benign group, n=50), and normal ovarian tissue(control group, n=50)were detected by the SP immunohistochemical, and their role in the occurrence and development of epithelial ovarian cancer was analyzed. Results: The positive expression rate of EGFR and KRAS protein in cases group were higher than those in benign group and control group(P<0.05). No statistical difference of EGFR and KRAS protein between benign group and control group was found(P>0.05). The positive expression rate of EGFR and KRAS protein in serous adenocarcinoma group were higher than those in non-serous adenocarcinoma group, and the positive expression rate of EGFR and KRAS protein in III-IV epithelial ovarian tissue were higher than those in I-II epithelial ovarian tissue, and the the positive expression rate of EGFR and KRAS protein in medium, low differ- entiation group were higher than those in high differentiation group, the difference was statistically significant(P<0.05). There was posi- tive relationship of positive expression rate between EGFR and KRAS in patients with epithelial ovarian cancer tissue(r=0.469, P<0.05). Conclusion: The expression of EGFR and KRAS in epithelial ovarian cancer tissue is significantly increase, which may participate in the process of occurrence and development of epithelial ovarian cancer. And the positive expression rate is a positive relationship between EGFR and KRAS, combined detection can be helpful to diagnosis of epithelial ovarian cancer.